Dielectric Spectroscopy: Choosing the Right Approach - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Dielectric Spectroscopy: Choosing the Right Approach
This tutorial paper is meant to aid in dielectric-sensor selection


Pharmaceutical Technology
Volume 9, Issue 32, pp. 8293

The US Food and Drug Administration's process analytical technology (PAT) initiative reflects the need for improved quality control in the pharmaceutical industry. As the complexity of pharmaceutical products increases, quality control becomes more costly and difficult. New analytical instrumentation should be developed to address the quality control problems associated with more complex pharmaceutical products. Dielectric spectroscopy, one of many process analytical technologies, has been used for several decades. As any other technology, it is continuously evolving. New instrumentation, algorithms, and materials broaden the applicability and capabilities of this method. Selecting the optimal architecture for a sensing system intended for each specific application requires a good understanding of main principles and engineering trade-offs common for this field. This article is written primarily for field practitioners who need to make a judicious choice of the best measurement technique for their application. Main principles and design features of dielectric sensors are discussed in the framework of pharmaceutical applications.

The range of potential applications of dielectric spectroscopy is quite broad. Virtually any physical process change leads to changes in dielectric properties of samples. Process variability is a primary concern for the pharmaceutical industry (1). Exposure to mechanical and thermal stress can cause a change in the physical properties of pharmaceuticals. Such variations are important to control because physical properties generally determine the efficacy of the drug. For instance, tablet coatings control the rate of drug delivery within the body of a patient (2–5) and influence the bioavailability of the drug. In addition, coatings protect the active ingredient from chemically harsh environments in the body (6). Similarly, API content in a given sample determines the potency of the drug. The drying process of pharmaceuticals is critical because 70% of global granulated pharmaceutical product is made using wet granulation (7). In wet granulation, liquid binding gels are used to facilitate bonding between active ingredients. At this stage, it is important to measure moisture because specific moisture levels are required for the formation of the correct-size granules. Further, in high-shear wet granulation methods, incorrect moisture levels can lead to a process-induced transformation (PIT) (8). In these transformations, the properties of the active ingredients can change, resulting in reduced efficacy.

Overview of sensing methods

Process analytical technologies. A number of sensing technologies can be used to detect physical properties of pharmaceuticals. Most commonly used technologies include near infrared spectroscopy (NIR) and Raman spectroscopy. Digital imaging methods, optical methods, and dielectric spectroscopy also are used to measure various physical properties.

NIR spectroscopy is widely used to measure API content, distribution of contaminants, moisture content, and polymorphism determination (9). Similarly, Raman spectroscopy has demonstrated success in measuring pharmaceutical reaction times, polymorphism, and differences between solid-state forms (8).

Digital imaging methods are used to monitor particle size in pharmaceutical powders (10). Optical methods have been used for inspection of tablet coatings (6), measurement of constituent concentration of pharmaceutical powder mixtures (11), and quantitative analyses of ascorbic acid in pharmaceuticals (11, 12). For example, laser induced breakdown spectroscopy (LIBS) is used to measure coating thickness of tablets (13).

Previous work using dielectric spectroscopy. Dielectric spectroscopy is a promising method to study physical properties of pharmaceutical solutions, colloids, microcapsules, gels, and emulsions. Craig provides a thorough review of these applications (14), which are summarized in this section.

Pharmaceutical solutions are important because the solubility of a drug in the solvent directly influences its rate of disassociation in the body, which in turn impacts bioavailability. Dielectric properties such as the static dielectric constant of solutions has been used to study the solubility of cosolvent systems, reaction rates of pharmaceutical solutions, and drug stability (14).



Colloids are two-phase systems that consist of particles suspended in a medium. Each particle in a colloidal solution has an electrical layer surrounding it that determines the stability of the system by affecting the aggregation or disassociation of colloidal particles. As a result of these forces, dielectric response of colloidal solutions provides information about particle size in the colloidal solutions. For example, a study conducted by Paul and Vogey suggested an inverse-square dependency between particle radius and dielectric relaxation frequency of the medium (15). This relationship is illustrated in the following equation:

in which D is the diffusion coefficient of counterions with a particle radius of a, and f c is the loss peak frequency. The inverse-square relationship between relaxation frequency and particle radius was confirmed in a subsequent study (16).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
44%
Facility/environment problems
0%
Process development problems
11%
Production equipment downtime
11%
Raw material supply problems
11%
Regulatory restrictions
0%
Business decisions to limit production
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here